Alicia K. Morgans, MD, MPH, presented “Recognizing and Managing the Side Effects of Androgen Deprivation Therapy” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.

How to cite: Morgans, Alicia K. “Recognizing and Managing the Side Effects of Androgen Deprivation Therapy” September 13th, 2019. Accessed Dec 2023.​/

Recognizing and Managing the Side Effects of Androgen Deprivation Therapy – Summary:

Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the side effects of androgen deprivation therapy (ADT) and how urologists can mitigate them. She observes that up to 40% of non-metastatic prostate cancer patients are treated with ADT, and those patients tend to be older and have more comorbidities. Studies have suggested that comorbidities and advanced age interact with ADT to increase risk of cardiovascular disease and diabetes. ADT is also associated with increased risk of depression, cognitive changes, and possibly dementia, as well as greater frailty in patients. Urologists should be aware of these side effects so that they can assess their patients’ risk and plan accordingly with multidisciplinary teams to reduce mortality and morbidity and improve quality of life.

About The 5th Annual Prostate & Urologic Cancer Symposium:

The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Cross presented this lecture during the 5th iteration of this summit in 2019.

Please click here for further educational content from this conference.